Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors)

Diabetes Obes Metab. 2018 Feb;20(2):233-237. doi: 10.1111/dom.13102. Epub 2017 Sep 28.

Authors

Derek J Nunez¹, David D'Alessio¹

Affiliation

¹ Division of Endocrinology, Metabolism and Nutrition, Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina.

PMID: 28842950
DOI: 10.1111/dom.13102

No abstract available

MeSH terms

Animals
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Diabetes Mellitus, Type 2 / drug therapy
Diabetes Mellitus, Type 2 / metabolism
Drugs, Investigational / adverse effects
Drugs, Investigational / pharmacology*
Drugs, Investigational / therapeutic use
Glucagon-Like Peptide-1 Receptor / agonists*
Glucagon-Like Peptide-1 Receptor / metabolism
Humans
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / pharmacology*
Hypoglycemic Agents / therapeutic use
Molecular Targeted Therapy
Receptors, Glucagon / agonists*
Receptors, Glucagon / antagonists & inhibitors*
Receptors, Glucagon / metabolism
Signal Transduction / drug effects*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Drugs, Investigational
GLP1R protein, human
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Receptors, Glucagon
crotedumab